These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38197578)

  • 1. Urinary oxypurinol is a useful tool to assess adherence to allopurinol in clinical practice.
    Hasikova L; Bartl J; Stiburkova B
    Rheumatology (Oxford); 2024 May; 63(6):e174-e176. PubMed ID: 38197578
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma oxypurinol as a measure of adherence in clinical trials.
    Stamp LK; Merriman T; Frampton C; Zhang M; Wallace M; Miner JN; Dalbeth N
    Ann Rheum Dis; 2018 Feb; 77(2):313-314. PubMed ID: 28057666
    [No Abstract]   [Full Text] [Related]  

  • 3. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
    Keith MP; Gilliland WR
    Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
    Stamp L; Gow P; Sharples K; Raill B
    Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gout: beyond the stereotype.
    Jones RE; Ball EV
    Hosp Pract (1995); 1999 Jun; 34(6):95-102; discussion 102-3; quiz 133. PubMed ID: 10386113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting allopurinol response in patients with gout.
    Wright DF; Duffull SB; Merriman TR; Dalbeth N; Barclay ML; Stamp LK
    Br J Clin Pharmacol; 2016 Feb; 81(2):277-89. PubMed ID: 26451524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
    Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A
    Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An audit of a therapeutic drug monitoring service for allopurinol therapy.
    Kannangara DR; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO
    Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
    Kankam M; Hall J; Gillen M; Yang X; Shen Z; Lee C; Liu S; Miner JN; Walker S; Clauson V; Wilson D; Nguyen M
    J Clin Pharmacol; 2018 Sep; 58(9):1214-1222. PubMed ID: 29733447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.
    Zandman-Goddard G; Amital H; Shamrayevsky N; Raz R; Shalev V; Chodick G
    Rheumatology (Oxford); 2013 Jun; 52(6):1126-31. PubMed ID: 23392592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data.
    Lin LW; Teng GG; Lim AYN; Yoong JS; Zethraeus N; Wee HL
    Int J Rheum Dis; 2019 Apr; 22(4):545-554. PubMed ID: 30556300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
    Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An allopurinol adherence tool using plasma oxypurinol concentrations.
    Smith-Diaz N; Stocker SL; Stamp LK; Dalbeth N; Phipps-Green AJ; Merriman TR; Wright DFB
    Br J Clin Pharmacol; 2023 Jul; 89(7):1956-1964. PubMed ID: 36036094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
    J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.
    Roberts RL; Wallace MC; Phipps-Green AJ; Topless R; Drake JM; Tan P; Dalbeth N; Merriman TR; Stamp LK
    Pharmacogenomics J; 2017 Mar; 17(2):201-203. PubMed ID: 26810134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.
    Stamp LK; Merriman TR; Barclay ML; Singh JA; Roberts RL; Wright DF; Dalbeth N
    Semin Arthritis Rheum; 2014 Oct; 44(2):170-4. PubMed ID: 24925693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allopurinol use in a New Zealand population: prevalence and adherence.
    Horsburgh S; Norris P; Becket G; Arroll B; Crampton P; Cumming J; Keown S; Herbison P
    Rheumatol Int; 2014 Jul; 34(7):963-70. PubMed ID: 24390636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.